A series of adjacent peptides based on the human PPI sequence consisting of 110 amino acids were synthesized by Shanghai Sangon Biotech Company (Shanghai, China). PPI peptides were 14 to 16 amino acids long and overlapped by eight amino acids spanning the complete sequence of PPI (Table 2 ). All of the 13 peptides were pooled together as a peptide mixture (PM). Given that the different regions of PPI peptides are likely to have different magnitudes in triggering IFN‐γ–producing response, a set of five peptides with dominant epitopes previously reported to show positive CD4+ T cells response were used separately: B9‐23, C19‐A3, B1‐16, B10‐24, and B30‐C13 (Table S1 ). The purity of peptides was >95% using reverse phase HPLC and mass spectrometry. Pentaxim (Sanofi‐Aventis, Paris, France), containing diphtheria toxoid, haemophilus influenzae type B capsular polysaccharide, pertussis toxoid, tetanus toxoid, amd poliomyelitis, was a childhood vaccine widely used across China. It was adopted as a recall antigen, and OKT3 antibody was used as positive control antigen. The selected MHC class II peptide pool PLUS (Axxora, LCC, USA) containing peptides from human cytomegalovirus, Epstein‐Barr virus, influenza virus and tetanus toxin was also used for the specificity of T cell response.
Pentaxim
Manufactured by Sanofi
Sourced in France
Pentaxim is a pentavalent vaccine developed by Sanofi for the prevention of diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b infections. It is administered through intramuscular injection.
Automatically generated - may contain errors
Lab products found in correlation
3 protocols using pentaxim
1
Peptide-based Immune Response Analysis
2
Pediatric Vaccine Immunization Schedule
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The immunization schedule for all vaccines followed routine practice for administration of the concomitant pediatric vaccines and is shown in PCV13+P80 or PCV13 w/o P80 (both 0.5 mL) was injected intramuscularly into the left anterolateral thigh muscle (lot numbers 7-5095-001A and 7-5093-003A, respectively). PCV13+P80 contains 2.2 μg of each saccharide, except for 4.4 μg of serotype 6B, per 0.5-mL dose. The final formulation contains 0.02% P80, 5 mM succinate buffer, with 0.125 mg of aluminum as aluminum phosphate per 0.5-mL dose. PCV13 w/o P80 was identical to PCV13+P80 with the exclusion of P80. Both PCV13+P80 and PCV13 w/o P80 were prefilled in identical syringes with a 1" needle length. Other routine vaccines administered were 0.5 mL combination diphtheria, tetanus and pertussis + inactivated poliovirus (types 1, 2 and 3) + Haemophilus influenzae type b vaccine (Pentaxim; Sanofi Pasteur, Swiftwater, PA; lot number infant vaccination Z2-155-2, lot number toddler vaccination A2061-1); 0.5 mL hepatitis B recombinant vaccine (Engerix-B; GlaxoSmithKline, London, United Kingdom; lot number AHBVB138AI); and 0.5 mL combined live measles, mumps, and rubella vaccine (Priorix; GlaxoSmithKline, London, United Kingdom; lot number A69CA683A). All were injected into right anterolateral thigh muscle.
3
Toddler Vaccination Study: Dengue, MMR, Varicella
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Eighty toddlers were randomized and vaccinated identically to study step 2.
CYD-TDV was supplied as powder and solvent for suspension for injection. Each 0.5 mL dose of reconstituted vaccine contained 5 ± 1 log 10 cell-culture infectious dose 50% of each live, attenuated, recombinant dengue serotype 1-4 virus. The solvent for reconstitution consisted of 0.4% NaCl and 2.5% human serum albumin. CYD-TDV, MMR and varicella vaccines were administered as subcutaneous injections in the deltoid region of the upper arm. In the case of vaccine coadministration, injections were in opposite arms. The hepatitis A vaccine was administered as an intramuscular injection in the upper arm. All toddlers also received a diphtheria (D), tetanus (T), acellular pertussis (aP), inactivated poliovirus (IPV) and haemophilus influenzae type b (Hib) polysaccharide conjugated to tetanus protein (PRP~T) combined vaccine (DTaP-IPV//PRP~T; PENTAXIM; Sanofi Pasteur, France), approximately 9-10 months after MMR injection, in accordance with immunization schedule of the Philippines (Fig. 1).
CYD-TDV was supplied as powder and solvent for suspension for injection. Each 0.5 mL dose of reconstituted vaccine contained 5 ± 1 log 10 cell-culture infectious dose 50% of each live, attenuated, recombinant dengue serotype 1-4 virus. The solvent for reconstitution consisted of 0.4% NaCl and 2.5% human serum albumin. CYD-TDV, MMR and varicella vaccines were administered as subcutaneous injections in the deltoid region of the upper arm. In the case of vaccine coadministration, injections were in opposite arms. The hepatitis A vaccine was administered as an intramuscular injection in the upper arm. All toddlers also received a diphtheria (D), tetanus (T), acellular pertussis (aP), inactivated poliovirus (IPV) and haemophilus influenzae type b (Hib) polysaccharide conjugated to tetanus protein (PRP~T) combined vaccine (DTaP-IPV//PRP~T; PENTAXIM; Sanofi Pasteur, France), approximately 9-10 months after MMR injection, in accordance with immunization schedule of the Philippines (Fig. 1).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!